The facility has been designed to enable AMPAC to expand its scale up capabilities, as well as showcase the company’s continuous “zone reactor”. This uses up to seven reactors with capacities ranging from 0.25L to 1L, which it believes offers better yield and cleaner impurity profiles than batch processing.
In addition to these benefits Aslam Malik, president of AMPAC, believes that the US Food and Drug Administration’s Quality by Design initiative will see continuous processing gain prominence.
